This company has been marked as potentially delisted and may not be actively trading. Vital Therapies (VTL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VTL vs. AMRN, TNGX, ACRS, RZLT, ALMS, ACRV, PRQR, RAPT, PBYI, and NBTXShould you be buying Vital Therapies stock or one of its competitors? The main competitors of Vital Therapies include Amarin (AMRN), Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS), Rezolute (RZLT), Alumis (ALMS), Acrivon Therapeutics (ACRV), ProQR Therapeutics (PRQR), RAPT Therapeutics (RAPT), Puma Biotechnology (PBYI), and Nanobiotix (NBTX). These companies are all part of the "medical" sector. Vital Therapies vs. Amarin Tango Therapeutics Aclaris Therapeutics Rezolute Alumis Acrivon Therapeutics ProQR Therapeutics RAPT Therapeutics Puma Biotechnology Nanobiotix Amarin (NASDAQ:AMRN) and Vital Therapies (NASDAQ:VTL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings. Does the MarketBeat Community favor AMRN or VTL? Amarin received 475 more outperform votes than Vital Therapies when rated by MarketBeat users. However, 74.40% of users gave Vital Therapies an outperform vote while only 73.46% of users gave Amarin an outperform vote. CompanyUnderperformOutperformAmarinOutperform Votes84473.46% Underperform Votes30526.54% Vital TherapiesOutperform Votes36974.40% Underperform Votes12725.60% Does the media refer more to AMRN or VTL? In the previous week, Amarin had 3 more articles in the media than Vital Therapies. MarketBeat recorded 4 mentions for Amarin and 1 mentions for Vital Therapies. Amarin's average media sentiment score of 1.00 beat Vital Therapies' score of 0.00 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vital Therapies 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more volatility & risk, AMRN or VTL? Amarin has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Vital Therapies has a beta of 3.51, meaning that its stock price is 251% more volatile than the S&P 500. Which has better valuation and earnings, AMRN or VTL? Vital Therapies has lower revenue, but higher earnings than Amarin. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$228.61M0.78-$59.11M-$0.20-2.16Vital TherapiesN/AN/A-$41.47MN/AN/A Is AMRN or VTL more profitable? Vital Therapies has a net margin of 0.00% compared to Amarin's net margin of -16.33%. Amarin's return on equity of -7.22% beat Vital Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Amarin-16.33% -7.22% -4.96% Vital Therapies N/A -235.33%-182.35% Do analysts rate AMRN or VTL? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Vital Therapies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in AMRN or VTL? 22.3% of Amarin shares are owned by institutional investors. Comparatively, 15.5% of Vital Therapies shares are owned by institutional investors. 2.0% of Amarin shares are owned by company insiders. Comparatively, 33.9% of Vital Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryAmarin beats Vital Therapies on 9 of the 14 factors compared between the two stocks. Remove Ads Get Vital Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTL vs. The Competition Export to ExcelMetricVital TherapiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.12M$6.77B$5.58B$7.92BDividend YieldN/A2.80%5.35%4.04%P/E RatioN/A7.1123.1218.81Price / SalesN/A205.89369.1988.69Price / CashN/A65.6738.1634.64Price / Book3.676.146.704.18Net Income-$41.47M$142.11M$3.20B$247.10M Vital Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTLVital TherapiesN/A$1.07-2.3%N/A-19.9%$45.12MN/A0.0010Gap UpAMRNAmarin0.9537 of 5 stars$0.46+1.6%N/A-49.9%$190.76M$228.61M-5.16360Analyst ForecastTNGXTango Therapeutics1.6884 of 5 stars$1.74-1.1%$12.33+608.8%-83.2%$188.11M$42.07M-1.4790Short Interest ↑News CoverageGap DownACRSAclaris Therapeutics2.2953 of 5 stars$1.70+6.3%$11.67+586.3%+17.5%$183.46M$18.72M-3.27100Short Interest ↑RZLTRezolute2.8573 of 5 stars$3.03-0.7%$24.38+704.5%+20.7%$183.42MN/A-2.4840News CoveragePositive NewsALMSAlumisN/A$3.78+0.8%$26.00+587.8%N/A$178.50MN/A0.00N/AGap DownACRVAcrivon Therapeutics2.3176 of 5 stars$5.61+4.7%$23.67+321.9%-76.8%$174.67MN/A-2.0858Earnings ReportPRQRProQR Therapeutics1.9488 of 5 stars$1.65flat$9.50+475.8%-41.1%$173.60M$18.91M-5.16180Positive NewsRAPTRAPT Therapeutics3.4884 of 5 stars$1.53+16.8%$5.29+245.5%-86.2%$172.93M$1.53M-0.5580Gap DownPBYIPuma Biotechnology4.3514 of 5 stars$3.47-1.1%$7.00+101.7%-44.5%$172.15M$230.47M7.23200News CoveragePositive NewsNBTXNanobiotix2.5973 of 5 stars$3.62-0.1%$12.00+231.9%-43.7%$170.43M$36.22M0.00100 Remove Ads Related Companies and Tools Related Companies AMRN Competitors TNGX Competitors ACRS Competitors RZLT Competitors ALMS Competitors ACRV Competitors PRQR Competitors RAPT Competitors PBYI Competitors NBTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTL) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vital Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vital Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VTL Stock Free VTL Stock Alerts